JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Rhythm Pharmaceuticals Inc

Closed

SectorHealthcare

110.19 1.18

Overview

Share price change

24h

Current

Min

109.95

Max

110.55

Key metrics

By Trading Economics

Income

2.9M

-47M

Sales

16M

49M

Profit margin

-96.144

Employees

283

EBITDA

6.9M

-40M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+8.63% upside

Dividends

By Dow Jones

Next Earnings

4 Nov 2025

Market Stats

By TradingEconomics

Market Cap

1.5B

7.5B

Previous open

109.01

Previous close

110.19

News Sentiment

By Acuity

50%

50%

147 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Oct 2025, 18:41 UTC

Earnings

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 Oct 2025, 18:31 UTC

Earnings

Correction to Procter & Gamble to Focus on Innovation

24 Oct 2025, 16:25 UTC

Major Market Movers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 Oct 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 Oct 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 Oct 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 Oct 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 Oct 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 Oct 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 Oct 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 Oct 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 Oct 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 Oct 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 Oct 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 Oct 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 Oct 2025, 18:52 UTC

Earnings

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 Oct 2025, 18:41 UTC

Earnings

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 Oct 2025, 18:03 UTC

Earnings

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 Oct 2025, 18:02 UTC

Earnings

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 Oct 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 Oct 2025, 16:57 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 Oct 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 Oct 2025, 16:44 UTC

Market Talk
Earnings

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 Oct 2025, 16:39 UTC

Market Talk
Earnings

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 Oct 2025, 16:33 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 16:23 UTC

Earnings

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 Oct 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 Oct 2025, 16:07 UTC

Earnings

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer Comparison

Price change

Rhythm Pharmaceuticals Inc Forecast

Price Target

By TipRanks

8.63% upside

12 Months Forecast

Average 120 USD  8.63%

High 142 USD

Low 95 USD

Based on 13 Wall Street analysts offering 12 month price targets forRhythm Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

60 / 65.58Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

147 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat